1. Quick Facts
Category: Direct Fat Metabolism / Lipolytic
Risk Level: High/Experimental
Research Status: Early-Stage Experimental
Administration: Subcutaneous Injection
Typical Frequency: Daily
Estimated Half-Life: Short-Acting Compound
Primary Research Interest: Fat Loss / Adipose Tissue Reduction
This material is provided strictly for educational and informational purposes related to experimental compounds and peptide research. Adipotide is not approved for general human use and remains an investigational compound with limited human data. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
Adipotide is an experimental fat-loss compound designed to selectively target and disrupt blood vessels that supply white adipose tissue. Unlike GLP-1 receptor agonists and other metabolic compounds, Adipotide does not primarily work through appetite suppression or glucose regulation.
Research has demonstrated significant reductions in body fat and body weight in animal models, but human data remain limited. Safety concerns, particularly regarding kidney function, have restricted further development and contributed to its classification as a high-risk experimental compound.
What People Commonly Claim
- Rapid fat loss without dieting
- Selective destruction of body fat
- Permanent elimination of fat cells
- Superior fat loss compared with GLP-1 medications
- A direct “fat-burning” peptide that works independently of appetite control
What the Literature Actually Shows
- Adipotide was designed to target blood vessels supplying white adipose tissue rather than directly targeting fat cells themselves.
- Animal studies demonstrated significant reductions in body fat and body weight.
- Limited human research has been conducted compared with approved weight-management therapies.
- Kidney-related safety concerns have been observed and remain a major limitation to development.
- Long-term safety, efficacy, and durability of fat-loss effects in humans remain incompletely characterized.
3. Reconstitution Guide
- Vial Size: 5 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.5 mL
- Final Concentration: 2 mg/mL
At this concentration:
• 1 mg = 0.50 mL (50 units)
• 500 mcg = 0.25 mL (25 units)
• 250 mcg = 0.125 mL (12.5 units)
*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.
4. Route of Administration
Adipotide is most commonly discussed as a subcutaneous injectable compound in experimental research settings.
- Primary Route: SubQ Injection
- Alternative Routes Discussed: None commonly referenced
- Injection Timing Notes: Commonly administered in the morning, often while fasted
5. Common Research Protocols
- Product Strength: 2 mg/mL
- Typical Delivered Amount: 250 mcg daily for 2 weeks, increasing by 250 mcg every 2 weeks as tolerated
- Frequency: Daily, preferably in the morning while fasted
- Cycle Length: 8 weeks on / 16 weeks off
- Special Notes: Adipotide is unique among fat-loss compounds because it does not primarily target appetite, glucose regulation, or metabolic rate. Instead, it was designed to selectively disrupt blood vessels that supply white adipose tissue, leading to a reduction in fat mass. Most published research has been limited to animal studies, and concerns regarding kidney-related side effects have been reported at higher exposures. Because human research remains limited, Adipotide should be considered an early-stage experimental compound.
6. Mechanism of Action
Adipotide targets receptors found on blood vessels supplying white adipose tissue. Once bound, it delivers a pro-apoptotic signal that disrupts these vessels and reduces the blood supply available to fat cells.
By selectively targeting adipose vasculature, Adipotide was designed to reduce fat mass through direct effects on adipose tissue rather than through appetite suppression or metabolic manipulation.
7. Potential Benefits
- Reduction in body fat mass
- Reduction in body weight
- Targeted effects on white adipose tissue
- Potential improvement in body composition
- Does not rely on appetite suppression mechanisms
8. Potential Risks / Side Effects
High/Experimental
- Kidney function abnormalities
- Increased creatinine levels
- Fatigue
- Nausea
- Injection-site reactions
- Unknown long-term safety profile
- Limited human research data
9. Half-Life
Published literature does not clearly establish a clinically relevant half-life for Adipotide. Research interest is generally focused on cumulative biological effects rather than maintenance of steady-state concentrations.
Because the compound remains highly experimental, pharmacokinetic data in humans are limited.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Kidney disease or impaired renal function
- Cardiovascular disease
- Pregnancy or breastfeeding
- Active cancer or cancer history
- Use with other investigational compounds without appropriate supervision
12. Further Study
Overview Article
Targeted Ablation of Adipose Tissue Through Peptide-Directed Proapoptotic Therapy
Preclinical Evidence
Advanced Reading
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Proceedings of the National Academy of Sciences (PNAS)
- Nature
- Peer-reviewed obesity and metabolism journals
14. Last Reviewed
June 2026